News
Talecris CEO plans to expand business after termination of acquisition deal with CSL
News&Observer, Raleigh, NC
The top executive at Talecris Biotherapeutics vowed to continue expanding the company’s business, after its $3.1 billion buyout by an Australian company was scrapped Monday.
The proposed deal with CSL Ltd., announced last August, would have been one of the Triangle’s largest corporate marriages. Talecris is based in Research Triangle Park and has a large drug manufacturing plant in Clayton.
But the deal raised red flags at the U.S. Federal Trade Commission, which worried that the combination would hurt competition and raise prices for medicines made from blood plasma. Last month the FTC asked a federal judge to block the buyout.
